The Pennsylvania Supreme Court has denied Johnson & Johnson’s request to overturn the $70 million Risperdal verdict upheld by a Superior court panel of judges last year. The case, A.Y. v. Janssen Pharmaceuticals,

As the COVID-19 pandemic continues to plague America, worsening the opioid crisis that has plagued the nation for decades, litigation to recoup the cost of fighting the opioid crisis has stalled. While local

The opioid crisis has highlighted problems with Pennsylvania’s prescription drug monitoring system. Over the past few years the Pennsylvania Department of Health has worked on a statewide database for monitoring schedule II –

A DC Circuit court upheld a federal judge’s ruling striking down the Department of Health and Human Services’ new rule requiring drug companies to disclose the price of a 30 day supply in

A new court filing against big American pharmacy retailers has been submitted in the multi-district litigation in Ohio Federal Court overseen by Judge Dan Polster. The complaint accuses major pharmacies, including CVS, Rite

April 2020 Update: Stephen Sheller has been recognized by the American Association for Justice with AAJ’s 2019 Top Verdict Award. “Each year, American Association for Justice releases the Top Verdicts Litigation Packet, featuring

A recent ProPublica investigative report calls into question the Trump Administration’s commitment to ending the opioid crisis, criminally charging those responsible, and ensuring that protections are in place to prevent another crisis. Even

The Pennsylvania Supreme Court declined to hear Janssen Pharmacuetical’s request for an appeal of a lower courts decision to reinstate the lawsuit of a Texas man who took Risperdal as a child. The Pennsylvania Superior Court’s decision to allow

In a rare admission to PBS Frontline & the Finical Times, a pharmaceutical executive acknowledged that he knowingly orchestrated an illegal scheme to boost sales of a powerful opiate painkiller believing there would be no

Philadelphia Court of Common Pleas Judge Kenneth Powell reduced an October 2019 $8 billion punitive damages verdict against J&J to $6.8 million. A jury had awarded the figure over allegations that J&J’s drug